C3 nephritic factor (C3NeF) was used to assess the formation of the fluid-phase amplification convertase, C3bBb, in 37 serum specimens from 24 patients with systemic lupus erythematosus (SLE). C3b,Bb formation was measured by the concentration of Ba 
Introduction
From data accumulated in recent years, investigators have inferred that certain defects in the serum complement system would predispose to immune complex disease (1, 2) . The removal of immune complexes from the circulation and their disposal by the mononuclear phagocyte system is dependent on the deposition of C3b on the complex (3) . Specifically, the deposition of C3b results in a reduction in complex size (4) , in an increase in solubility (4) , and in binding of the complex to phagocytes, which leads to their ingestion (5, 6) . Deposition of C3b is initiated by immune complex activation of the classical pathway and the formation of the classical convertase, C4b,2a. The deposited C3b, with factors B, D, and properdin, forms the more vigorous amplification C3 convertase, C3b,Bb,P (7) , which results in further C3b deposition. Thus, the proteins essential for solubilization are C3 and factors B, D, and P. In addition, factors H and I are necessary to regulate the reaction leading to C3b,Bb formation (8) . In vivo, the erythrocyte C3b receptor (CR-1) may substitute for factor H (9) . In whole serum, solubilization can occur in the absence of the classical pathway, but with this pathway intact it is more rapid and complete (2) .
A functional defect in the serum complement system that inhibits C3b deposition could therefore result in disease by compromising the processing and clearance of potentially pathogenic complexes. It is well known that specific inherited defects in the complement system can be associated with immune complex disease (10) , but in most patients such defects have not been found. Immune complex disease may be accompanied by an acquired hypocomplementemia, but it is often not sufficiently severe to affect immune complex processing.
This report presents evidence for a circulating inhibitor of fluid-phase amplification convertase formation in the sera of patients with systemic lupus erythematosus (SLE).' This inhibition has been demonstrated by using the C3 nephritic factor (C3NeF) for functional assessment of the C3b amplification loop. The response of the loop to C3NeF has been quantitated in two ways. First, the fragment of factor B, designated Ba, formed when factor B is activated (1 1, 12) , has been measured as an index of amplification convertase (C3b,Bb) formation. Second, the loss of the B antigen of C3 has been used as a measure of C3 conversion (13, 14) . Both convertase formation and C3 conversion in response to C3NeF were inhibited in the sera of patients with SLE. In addition, inactivation of H by adding to serum an F(ab')2 fragnient of anti H has been used to assess spontaneous fluid-phase convertase formation. Again, amplification loop turnover was inhibited in the sera of patients with SLE relative to that in normal human serum (NHS).
Methods
Patient data. The studies were done on sera from 24 patients with SLE, from 41 healthy hospital personnel (NHS), and on a pooled NHS (PNHS) from 12 donors. Blood was collected by venipuncture and allowed to clot in glass tubes for 30 min at room temperature. The serum was separated and either used fresh or stored at -700C. The patients with SLE met the American Rheumatology Association criteria 1. Abbreviations used in this paper: C3NeF, C3 nephritic factor; CRP, C-reactive protein; NHS, normal human serum; PEG, polyethylene glycol; PNHS, pooled NHS; RID, radial immunodiffusion; SDS-PAGE, SDS polyacrylamide gel electrophoresis; SLE, systemic lupus erythematosus.
for the diagnosis. All except one were female and all were under the age of 21 yr. Extrarenal SLE was considered to be present in 5 of the 24 patients. They had normal urinalyses and serum creatinine concentrations < 1.1 mg/dl. A patient with renal SLE was considered to be in remission when clinical evidence of disease activity such as rash, arthritis, and neutropenia had disappeared and the serum C3 level, if initially low, had come into the normal range. During a clinical remission, the urinalysis was usually still abnormal but was improved compared with that during periods of active disease.
Measurement ofserum complement components. The complement proteins, C3, and factors H, I, and B, were measured by radial immunodiffusion (RID). For measurement of serum C3 levels, monospecific antiserum to the A determinant of C3 was used (13) . The methods for quantitation for the other proteins have been described previously (15, 16) . All antisera were rendered monospecific by absorption and subjected to octanoic acid precipitation (17) to obtain a preparation enriched in IgG.
Protein isolation. C3 was isolated from pooled normal plasma by the method of Hammer et al. (18) with the addition of a precipitation step using 12% polyethylene glycol (PEG) 4,000 (Sigma Chemical Co., St. Louis, MO) before chromatography on DEAE Sephacel (Pharmacia Fine Chemicals, Piscataway, NJ). Additional PEG was added to the 12% supernatant to a final concentration of 45%. The resulting precipitate was redissolved and used as a source for the purification of factor B. The method of Lambris et al. (19) was used with the omission of C3b agarose chromatography and the addition of immunoabsorption on a column of anti-Cl inhibitor conjugated to Sepharose 4B. H was isolated from a pool of enriched fractions after DEAE Sephacel chromatography. Contaminants were removed by passage over DNA cellulose (Sigma Chemical Co.) in 10 mM sodium phosphate, pH 6.8, 50 mM sodium chloride, 5 mM EDTA, and elution by a gradient to 0.4 M sodium chloride (20) . C3 and H were also isolated from a pool of sera drawn on several dates from a patient with SLE who consistently demonstrated excess inhibitor. The starting volume was 8 ml and the same procedure was used as for the proteins from normal plasma.
Functionally pure I was obtained by passage of EDTA treated normal serum over a column of Sepharose 4B to which goat anti-I had been conjugated. Adsorbed material was eluted with 3.5 M NaSCN and dialyzed into phosphate-buffered saline (PBS). All purified components were homogeneous by polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) and produced bands of appropriate molecular weights. Purified components were dialyzed against PBS before use. IgG was separated from the serum of one patient and from normal serum by ion exchange chromatography on DEAE Sephacel. The concentration of the IgG preparation was adjusted to that in the original serum and it was dialyzed against veronal-buffered saline with physiologic concentrations of Ca++ and Mg++. Measurement of C3 conversion and amplification convertase formation. C3 conversion was assessed, as previously described (14) Mixing experiments to detect free inhibitor. Two target sera were used in mixing experiments. The first was the pool of NHS (PNHS) described above. The second was obtained from a healthy individual who was presumably heterozygous deficient in H (H concentration, 3.2 SD below the mean). This serum is designated low H target serum. The concentrations of other components in this target serum, measured immunochemically and expressed in standard deviations from the mean, were: Clq, +0.7; C2, -0.1; C4, -0.3; C3, -1.8; factor B, -1.5; factor I, -0.3; and factor P, -1.7. Both target sera were stored in aliquots at -70°C that were discarded after use.
In preliminary mixing experiments to detect free inhibitor, the two target sera, SLE sera and 1:1 mixtures of the two were mixed with various dilutions of the C3NeF preparation with the tubes immersed in an ice bath. After removing aliquots for the measurement of Ba, the tubes were incubated for 5 min at 37°C, returned to the ice bath, and aliquots again removed for measurement of Ba. As a result of these observations, the method used for surveying large numbers of serum specimens for free inhibitor used the low H target serum. 10 [25] [26] [27] [28] [29] and none contained preformed Ba. In NHS, a direct relationship between the quantity of Ba formed and of C3 converted at 5 mmn was observed (Fig. 2) .
This relationship is compatible with the assumption that Ba formation measures amplification convertase (C3b,Bb) formation. A plateau is reached at high Ba concentrations because at these concentrations C3 conversion approached 100%. The relationship also held in SLE sera in that C3 conversion was reduced commensurate with the inhibition in Ba formation. Thus, the inhibition appears to be limited to convertase formation; that convertase that is formed in SLE sera functions normally.
As can be seen in Fig. 2 , in the 33 specimens of NHS incubated with C3NeF under the standard conditions employed, the concentration of Ba varied from 1.4 to 8 mg activated factor B/dl. To determine the basis for this variability, Ba generation was plotted vs. the serum concentrations of H, a protein which combines with C3b to prevent convertase formation and which mediates decay dissociation of convertase once formed (25) . It is apparent from this plot, shown in Fig.  3 , that in specimens of NHS there was an inverse relationship between the quantity of Ba generated and the serum H concentration (r =-0.68). Graphs of Ba generation vs. I concentration or for Ba generation vs. H + I concentrations, each expressed as percentage of normal, showed greater scatter than that for Ba versus H concentration.
Ba generation by C3NeF in the serum of patients with SLE is also shown in Fig. 3 . In nearly all cases, less Ba was formed than in NHS and in some specimens none was formed. In contrast to NHS, no relationship was discernible between the concentration of H in SLE sera and the quantity of Ba formed.
Ba formation was compared in serum specimens with various H concentrations by dividing the actual Ba concentration by the Ba concentration expected for the serum H concentration as determined from the regression line in Fig.  3 . Values for this ratio for all 24 patients with SLE and 41 normal subjects are shown in Fig. 4 . In the normal subjects, the ratio ranged from 0.6 to 1.6. In contrast, the ratios in six patients with SLE with renal involvement studied at the onset of their disease before institution of therapy with corticosteroid were consistently <0.6 and usually <0. During clinical remission, however, 2 of 14 patients had normal ratios (>0.6), but in many the ratio was still very low. Ratios similar to those of patients in remission were found in five patients with extrarenal lupus who were not being treated with corticosteroid. The roles ofC3 andfactor B in the inhibition ofconvertase formation. Because C3b, the activated form of C3, is essential To clarify these conflicting results, the dose response to C3NeF in mixtures containing SLE sera and either PNHS or low H target serum was studied. As illustrated in Fig. 6 A, when an SLE serum forming little Ba with C3NeF (Ba/Ba expected <0.1) was mixed with either PNHS or low H target serum, less Ba was produced than expected, which indicated the presence of free inhibitor, until very high doses of C3NeF were used. The inhibition was again most apparent with the low H target serum. In contrast, as illustrated in Fig. 6 Fig. 7 . In 16 specimens of NHS, this ratio ranged from 1.0 to 1.5. The reason this ratio averages greater than unity is not clear. Numerous specimens of SLE serum in which inhibition of convertase formation could be demonstrated were tested by this method, and many of the specimens gave inhibition ratios <1.0, which indicated the presence of excess inhibitor (Fig. 7) . There was no significant difference between the inhibition ratios in specimens obtained at the onset of disease, during clinically active disease, or during clinical remission. Of the specimens from five patients with extrarenal SLE, free inhibitor could not be demonstrated in four.
Mixing experiments were performed longitudinally on serum specimens from five patients (Fig. 8) . The amount of inhibition varied little in individual patients whether the disease was at onset, under treatment, or in remission, which indicated that when free inhibitor is demonstrable, it is present at a relatively constant level over long periods.
Relation between inhibition of Ba generation and the inhibition index in mixing experiments. There was only a rough correlation between the amount of Ba generated in SLE serum in response to C3NeF and the amount of free inhibitor as assessed by mixing experiments. As shown in Fig. 9 , excess inhibitor could be demonstrated in all of 14 serum specimens with a very low (<0.1) ratio of Ba to Ba expected for the serum H concentration. In specimens in which the ratio of Ba to Ba expected was >0.1, free inhibitor could be demonstrated in only half. F(ab')2 anti-H augmented amplification convertase formation. Spontaneous amplification convertase formation occurs with the addition F(ab')2 anti-H to serum. Thus, the F(ab')2 anti-H provides an independent means of detecting the inhibitor. Absence of the Fc portion of the anti-H prevents classical pathway activation by the resulting H-anti-H immune complex. F(ab')2 anti-H was added to serum specimens in an amount which in preliminary experiments was found to reduce the serum H concentration about two-thirds, the mixture incubated 5 min at 37°C, and Ba formation compared with that produced by C3NeF. The data for seven specimens of NHS and 21 specimens from patients with SLE, given in Fig. 10 resulting from incubation with F(ab')2 anti-H correlated well with that produced by C3NeF. At the dosages used, F(ab')2 anti-H formed more Ba than did C3NeF. Dependence of the inhibitor on factor H. In the course of experiments employing the F(ab')2 anti-H, it was found that the inhibitor is not demonstrable in the absence of H. Experiments demonstrating this are shown in Fig. 11 . To PNHS and serum from patients with SLE was added a sufficient quantity of F(ab')2 anti-H to remove virtually all the H, which produced a serum designated RH. To aliquots of these preparations, incremental amounts of purified normal H were added. The mixtures were then incubated for 5 min at 370C, returned to ice, and EDTA added to stop the reaction.
As shown in Fig. 11 , Ba formation, expressed as percentage 10 and that any H in that milieu would be more effective. To confirm this, H was isolated from SLE serum and added incrementally to an RH made from PNHS. As shown in Fig.  1 1, In a further effort to detect a component abnormality in SLE serum, the ability of H and C3b from a patient with SLE to interact with normal C3b and H was monitored in mixtures of purified components. After SDS-PAGE, reduced C3b produces two protein bands representing the alpha' and beta chains. As C3b is degraded to iC3b by H and I, the alpha' chain is cleaved into two smaller fragments (26) . Thus the dose-response of a constant amount of C3b to increments of H can be measured by the decrease in density of the alpha' chain band relative to the constant density of the beta chain. Densitometric measurement of the protein bands after SDS-PAGE of the incubated mixtures show that H derived from SLE serum was no more effective than the H derived from PNHS in cleaving the alpha' chain of C3b (Fig. 12 ). In the same way, it was demonstrated that C3b derived from SLE serum was not more susceptible to cleavage by H and I than its normal counterpart (data not shown). Neither the C3 nor the H preparations showed evidence of proteolysis and both were free of contaminating proteins.
Simulation of inhibitor effect by heparin. Heparin, added to serum, has recently been shown to bind to H and potentia the ability of H to inactivate C3b (27) . It was demonstrat further in the study that, as in SLE serum, inhibition conve-tase formation by heparin was not demonstrable in ti absence of H and the inhibitory effect of heparin could 1 restored by addition of purified H to the mixture. The abili of heparin to prevent convertase formation was confirmed i the present study; Ba formation in response to incubation NHS with C3NeF was inhibited slightly at a heparin concei tration of 20-30 ,g/ml and markedly inhibited at a concentrn tion of 100 gg/ml (Fig. 13) . As would be expected, activatio of C3 was depressed commensurate with the depression of E formation.
It was shown previously (27) that addition of heparin t serum increased the electrophoretic mobility of H. This wa also observed in this laboratory. However, electrophoreti analysis of SLE serum containing excess inhibitor showed I to have the same mobility as the H in NHS.
Attempts to further identify the inhibiting factor. Becaus of the diversity of autoantibodies observed in patients wit SLE, the possibility that an immunoglobulin was increasin the sensitivity of C3b to H was investigated. The IgG fraction of NHS and SLE-4 serum with high inhibitor content wer isolated by ion exchange chromatography. Incremental amount of the isolated IgG were mixed with NHS, C3NeF added, an( the mixture incubated at 370C for 5 min. As shown in Fig   14, (Fig. 1 ). There was a linear relationship between the h quantity of Ba formed and the extent of C3 conversion (Fig.   f 2), which indicated that Ba formation reflects effective converr tase formation. It was observed that the quantity of convertase formed in NHS was, to some extent, inversely related to the H concentration (Fig. 3) (Fig. 3) .
SLE and normal sera with various H concentrations were compared by correcting convertase formation for serum H concentration (Fig. 4) . The inhibition of convertase formation was demonstrable at all levels of disease activity and in the presence or absence of therapy. Inhibition of convertase formation was not related to a deficiency pf any complement component measured. In particular, C3 and factor B were present in normal concentrations in the sera of a majority of the patients (Fig. 5 ), including some with severe inhibition. Furthermore, addition of purified normal factor B or C3 to SLE sera did not restore convertase formation (Table I) .
Mixing experiments not only gave evidence that in some sera, an inhibitor of convertase formation was present in excess ( Fig. 7) , but also shed light on the nature of the inhibition.
Comparison of the results of experiments employing variable quantities of C3NeF and using PNHS and a serum with a low H concentration as target sera (Fig. 6, A (Fig. 8) . Sera producing little Ba with C3NeF addition were most frequently found to have excess inhibitor in mixing experiments (Fig. 9) . In additional studies, spontaneous convertase formation in response to partial depletion of factor H from serum by addition of F(ab')2 anti-H was found to be inhibited in SLE serum to the same extent as convertase formation produced by C3NeF (Fig. 10) . However, in SLE serum from which H had been totally or subtotally removed, inhibition of convertase formation could not be demonstrated (Fig. 1 1) (Fig. I 1) . Since Ba generation was markedly inhibited by the addition of very small amounts of normal H to the H-depleted SLE serum, it appears that some factor in that serum potentiated the interaction of C3b and H. Secondly, H isolated from a specimen of SLE serum was added to an RH made from PNHS. The relationship between H concentration and spontaneous Ba generation was essentially the same as when normal H was added to an RH of PNHS (Fig. 11) . Third, SDS-PAGE of mixtures ofpurified C3b, H, and I demonstrated no abnormality in the functional interaction of SLE-derived H with C3b or SLE-derived C3b with H (12) .
In summary, the inhibition is not due to an intrinsic abnormality in C3 or H. It appears to be due to an entity that can potentiate the interaction of C3b with H but does not copurify with either. In support of this hypothetical mechanism, soluble heparin has recently been shown to potentiate the ability of H to inactivate C3b (27) . However, unlike heparin, the inhibitor in SLE serum appears to interact more loosely with H and does not change its electrophoretic or chromatographic properties. It was shown that the inhibitor was not IgG and that it had a molecular weight in excess of 12,000-14,000.
The increased sensitivity of fluid-phase C3b to H, observed in the present study, is reminiscent of the changes in H sensitivity of membrane-bound C3b in the presence of certain membrane constituents. It is well known that membraneassociated sialic acid greatly increases the H sensitivity of C3b bound to that surface (28, 29) . Others have shown that H sensitivity also increases linearly with the number of molecules of heparin bound to zymozan particles (30) . C-reactive protein (CRP) appears to have the same effect; C3b deposited on Streptococcus pneumoniae that has been reacted with CRP will bind twice as much H as that bound to S. pneumoniae not reacted with CRP (31). It is not clear how these surface molecules alter the sensitivity of C3b to H. To date, no naturally occurring substance has been described which in the fluid phase will increase the sensitivity of C3b to H as observed in the present study.
Studies by others (32-36) employing the sera of patients with immune complex disease suggest that the inhibitor of fluid-phase convertase formation described here would reduce the ability of serum to solubilize complexes. These studies have measured the ability of serum to either solubilize preformed immune complexes (4, 33) or to prevent precipitation of complexes formed by antigen and antibody added separately to serum (34) . Normal serum both solubilizes preformed complexes and inhibits precipitation of de novo complexes. Solubilization requires an intact alternative pathway but is more rapid and complete if the classical pathway is intact also (7) . Inhibition of precipitation requires that both the classical and alternative pathway be intact (34) . Both depend on the deposition of C3b on the lattice. Two groups (32, 33) have shown that preformed complexes are poorly solubilized by SLE sera and Naama et al. (35) showed that immune complexes formed in SLE sera precipitated rather than remaining in solution. The same was true of sera from patients with seropositive rheumatoid arthritis, which indicated that the abnormality in SLE was not necessarily the result of hypocomplementemia. The authors then demonstrated (36) that complexes formed in 1:1 mixtures of NHS and sera from patients with rheumatoid arthritis precipitated, which suggested a circulating inhibitor of solubilization present in excess. The inhibitor was more frequently and readily demonstrable when serum specimens from patients were heated to 56°C for 30 min. It was shown to be a protein but was not further characterized.
Alternative pathway activity, measured by hemolysis of rabbit red blood cells, has been found to be inhibited in the sera of patients with SLE (37) . The inhibition correlated well with serum C3 and C4 levels, leading the authors to conclude that consumption of components through triggering of the C3b amplification loop by the in vivo classical pathway activation had decreased the activity of the alternative pathway. This explanation appears to be correct, since the correlations they observed would not be predicted if an inhibitor such as described in the present paper were responsible for the alternative pathway inhibition. An inhibitor that increases the sensitivity of fluid-phase C3b or fluid-phase C3b,B to H would not demonstrably affect C3b or C3b,B present on an alternative pathway activator, such as rabbit red cells. Much further study will be necessary to identify the inhibitor and determine whether it is the same as, or similar to, the inhibitor of immune complex solubilization in SLE and rheumatoid arthritis described by others (32, 33, 36) and whether it has a role in the pathogenesis of immune complex disease.
